Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veregen 10% Ointment for Actinic Keratosis
NCT07137819Phase 3Recruiting
- Sponsor
- Aresus Pharma
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sinecatechins in actinic keratosis (AK), sponsored by Aresus Pharma. Started Sep 2024; status: recruiting.
02
Drugs
sinecatechins
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT07137819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137819.